Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

Cell Reports

Volumn 11, Issue 7, 2015, Pages 1018-1030

  Corrales, Leticia ^a   Glickman, Laura Hix ^b   McWhirter, Sarah M ^b   Kanne, David B ^b   Sivick, Kelsey E ^b   Katibah, George E ^b   Woo, Seng Ryong ^a   Lemmens, Edward ^b   Banda, Tamara ^b   Leong, Justin J ^b   Metchette, Ken ^b   Dubensky, Thomas W ^b   Gajewski, Thomas F ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Aduro BioTech Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC DINUCLEOTIDE DERIVATIVE; DINUCLEOTIDE; MEMBRANE PROTEIN; MLRR S2; STIMULATOR OF INTERFERON GENE PROTEIN; UNCLASSIFIED DRUG; VADIMEZAN; ANTINEOPLASTIC AGENT; CYCLIC NUCLEOTIDE; MPYS PROTEIN, MOUSE; XANTHONE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CD8+ T LYMPHOCYTE; COLON CARCINOMA; CONTROLLED STUDY; DISTANT METASTASIS; DRUG EFFICACY; DRUG POTENCY; GENE ACTIVATION; GENE FREQUENCY; HUMAN; HUMAN CELL; IMMUNOLOGICAL MEMORY; LUNG METASTASIS; MELANOMA; MEMORY CELL; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; SYSTEMIC THERAPY; TOXICITY TESTING; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; C57BL MOUSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE INACTIVATION; GENETIC TRANSFECTION; IMMUNOLOGY; MACROPHAGE; NEOPLASMS, EXPERIMENTAL; POLYMERASE CHAIN REACTION; SYNTHESIS; TUMOR CELL LINE; WESTERN BLOTTING;

MURINAE; MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE KNOCKOUT TECHNIQUES; HUMANS; MACROPHAGES; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; NUCLEOTIDES, CYCLIC; POLYMERASE CHAIN REACTION; TRANSFECTION; TUMOR MICROENVIRONMENT; XANTHONES;

EID: 84929705879     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.04.031     Document Type: Article

References (54)

1. Ablasser A., Goldeck M., Cavlar T., Deimling T., Witte G., Röhl I., Hopfner K.P., Ludwig J., Hornung V. cGAS produces a 2'-5'-linked cyclic dinucleotide second messenger that activates STING. Nature 2013, 498:380-384.
2. Baguley B.C., Ching L.-M. Immunomodulatory actions of xanthenone anticancer agents. BioDrugs 1997, 8:119-127.
3. Blank C., Brown I., Peterson A.C., Spiotto M., Iwai Y., Honjo T., Gajewski T.F. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by Tcell receptor (TCR) transgenic CD8+ Tcells. Cancer Res. 2004, 64:1140-1145.
4. Brody J.D., Ai W.Z., Czerwinski D.K., Torchia J.A., Levy M., Advani R.H., Kim Y.H., Hoppe R.T., Knox S.J., Shin L.K., et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J.Clin. Oncol. 2010, 28:4324-4332.
5. Burdette D.L., Vance R.E. STING and the innate immune response to nucleic acids in the cytosol. Nat. Immunol. 2013, 14:19-26.
6. Burdette D.L., Monroe K.M., Sotelo-Troha K., Iwig J.S., Eckert B., Hyodo M., Hayakawa Y., Vance R.E. STING is a direct innate immune sensor of cyclic di-GMP. Nature 2011, 478:515-518.
7. Cavlar T., Deimling T., Ablasser A., Hopfner K.P., Hornung V. Species-specific detection of the antiviral small-molecule compound CMA by STING. EMBO J. 2013, 32:1440-1450.
8. Chandra D., Quispe-Tintaya W., Jahangir A., Asafu-Adjei D., Ramos I., Sintim H.O., Zhou J., Hayakawa Y., Karaolis D.K., Gravekamp C. STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer. Cancer Immunol Res 2014, 2:901-910.
9. Conlon J., Burdette D.L., Sharma S., Bhat N., Thompson M., Jiang Z., Rathinam V.A.K., Monks B., Jin T., Xiao T.S., et al. Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid. J.Immunol. 2013, 190:5216-5225.
10. Deng L., Liang H., Xu M., Yang X., Burnette B., Arina A., Li X.-D., Mauceri H., Beckett M., Darga T., et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 2014, 41:843-852.
11. Diamond M.S., Kinder M., Matsushita H., Mashayekhi M., Dunn G.P., Archambault J.M., Lee H., Arthur C.D., White J.M., Kalinke U., et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J.Exp. Med. 2011, 208:1989-2003.
12. Diner E.J., Burdette D.L., Wilson S.C., Monroe K.M., Kellenberger C.A., Hyodo M., Hayakawa Y., Hammond M.C., Vance R.E. The innate immune DNA sensor cGAS produces a noncanonical cyclic dinucleotide that activates human STING. Cell Rep. 2013, 3:1355-1361.
13. Dubensky T.W., Kanne D.B., Leong M.L. Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants. Ther Adv Vaccines 2013, 1:131-143.
14. Ebensen T., Schulze K., Riese P., Link C., Morr M., Guzmán C.A. The bacterial second messenger cyclic diGMP exhibits potent adjuvant properties. Vaccine 2007, 25:1464-1469.
15. Ebensen T., Schulze K., Riese P., Morr M., Guzmán C.A. The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant. Clin. Vaccine Immunol. 2007, 14:952-958.
16. Ebensen T., Libanova R., Schulze K., Yevsa T., Morr M., Guzmán C.A. Bis-(3',5')-cyclic dimeric adenosine monophosphate: strong Th1/Th2/Th17 promoting mucosal adjuvant. Vaccine 2011, 29:5210-5220.
17. Fitzgerald K.A., McWhirter S.M., Faia K.L., Rowe D.C., Latz E., Golenbock D.T., Coyle A.J., Liao S.M., Maniatis T. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol. 2003, 4:491-496.
18. Fuertes M.B., Kacha A.K., Kline J., Woo S.R., Kranz D.M., Murphy K.M., Gajewski T.F. Host type I IFN signals are required for antitumor CD8+ Tcell responses through CD8alpha+ dendritic cells. J.Exp. Med. 2011, 208:2005-2016.
19. Gaffney B.L., Veliath E., Zhao J., Jones R.A. One-flask syntheses of c-di-GMP and the [Rp,Rp] and [Rp,Sp] thiophosphate analogues. Org. Lett. 2010, 12:3269-3271.
20. Gajewski T.F., Woo S.R., Zha Y., Spaapen R., Zheng Y., Corrales L., Spranger S. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr. Opin. Immunol. 2013, 25:268-276.
21. Galon J., Pagès F., Marincola F.M., Angell H.K., Thurin M., Lugli A., Zlobec I., Berger A., Bifulco C., Botti G., et al. Cancer classification using the Immunoscore: a worldwide task force. J.Transl. Med. 2012, 10:205.
22. Gao P., Ascano M., Zillinger T., Wang W., Dai P., Serganov A.A., Gaffney B.L., Shuman S., Jones R.A., Deng L., et al. Structure-function analysis of STING activation by c[G(2',5')pA(3',5')p] and targeting by antiviral DMXAA. Cell 2013, 154:748-762.
23. Gao P., Ascano M., Wu Y., Barchet W., Gaffney B.L., Zillinger T., Serganov A.A., Liu Y., Jones R.A., Hartmann G., et al. Cyclic [G(2',5')pA(3',5')p] is the metazoan second messenger produced by DNA-activated cyclic GMP-AMP synthase. Cell 2013, 153:1094-1107.
24. Goins W.F., Huang S., Cohen J.B., Glorioso J.C. Engineering HSV-1 vectors for gene therapy. Methods Mol. Biol. 2014, 1144:63-79.
25. Gray P.M., Forrest G., Wisniewski T., Porter G., Freed D.C., DeMartino J.A., Zaller D.M., Guo Z., Leone J., Fu T.M., Vora K.A. Evidence for cyclic diguanylate as a vaccine adjuvant with novel immunostimulatory activities. Cell. Immunol. 2012, 278:113-119.
26. Harlin H., Meng Y., Peterson A.C., Zha Y., Tretiakova M., Slingluff C., McKee M., Gajewski T.F. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 2009, 69:3077-3085.
27. Hildner K., Edelson B.T., Purtha W.E., Diamond M., Matsushita H., Kohyama M., Calderon B., Schraml B.U., Unanue E.R., Diamond M.S., et al. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic Tcell immunity. Science 2008, 322:1097-1100.
28. Ishikawa H., Barber G.N. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 2008, 455:674-678.
29. Ishikawa H., Ma Z., Barber G.N. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 2009, 461:788-792.
30. Jassar A.S., Suzuki E., Kapoor V., Sun J., Silverberg M.B., Cheung L., Burdick M.D., Strieter R.M., Ching L.M., Kaiser L.R., Albelda S.M. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. Cancer Res. 2005, 65:11752-11761.
31. Jin L., Xu L.G., Yang I.V., Davidson E.J., Schwartz D.A., Wurfel M.M., Cambier J.C. Identification and characterization of a loss-of-function human MPYS variant. Genes Immun. 2011, 12:263-269.
32. Joseph W.R., Cao Z., Mountjoy K.G., Marshall E.S., Baguley B.C., Ching L.M. Stimulation of tumors to synthesize tumor necrosis factor-alpha insitu using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. Cancer Res. 1999, 59:633-638.
33. Kawarada Y., Ganss R., Garbi N., Sacher T., Arnold B., Hämmerling G.J. NK- and CD8(+) Tcell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J.Immunol. 2001, 167:5247-5253.
34. Kim S., Li L., Maliga Z., Yin Q., Wu H., Mitchison T.J. Anticancer flavonoids are mouse-selective STING agonists. ACS Chem. Biol. 2013, 8:1396-1401.
35. Konno H., Konno K., Barber G.N. Cyclic dinucleotides trigger ULK1 (ATG1) phosphorylation of STING to prevent sustained innate immune signaling. Cell 2013, 155:688-698.
36. Lara P.N., Douillard J.Y., Nakagawa K., von Pawel J., McKeage M.J., Albert I., Losonczy G., Reck M., Heo D.S., Fan X., et al. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J.Clin. Oncol. 2011, 29:2965-2971.
37. Li L., Yin Q., Kuss P., Maliga Z., Millán J.L., Wu H., Mitchison T.J. Hydrolysis of 2'3'-cGAMP by ENPP1 and design of nonhydrolyzable analogs. Nat. Chem. Biol. 2014, 10:1043-1048.
38. McWhirter S.M., Barbalat R., Monroe K.M., Fontana M.F., Hyodo M., Joncker N.T., Ishii K.J., Akira S., Colonna M., Chen Z.J., et al. A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP. J.Exp. Med. 2009, 206:1899-1911.
39. Niesen F.H., Berglund H., Vedadi M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat. Protoc. 2007, 2:2212-2221.
40. Postow M.A., Harding J., Wolchok J.D. Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. Cancer J. 2012, 18:153-159.
41. Prantner D., Perkins D.J., Lai W., Williams M.S., Sharma S., Fitzgerald K.A., Vogel S.N. 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) activates stimulator of interferon gene (STING)-dependent innate immune pathways and is regulated by mitochondrial membrane potential. J.Biol. Chem. 2012, 287:39776-39788.
42. Roberson S.M., Walker W.S. Immortalization of cloned mouse splenic macrophages with a retrovirus containing the v-raf/mil and v-myc oncogenes. Cell. Immunol. 1988, 116:341-351.
43. Römling U., Galperin M.Y., Gomelsky M. Cyclic di-GMP: the first 25 years of a universal bacterial second messenger. Microbiol. Mol. Biol. Rev. 2013, 77:1-52.
44. Sauer J.D., Sotelo-Troha K., von Moltke J., Monroe K.M., Rae C.S., Brubaker S.W., Hyodo M., Hayakawa Y., Woodward J.J., Portnoy D.A., Vance R.E. The N-ethyl-N-nitrosourea-induced Goldenticket mouse mutant reveals an essential function of Sting in the invivo interferon response to Listeria monocytogenes and cyclic dinucleotides. Infect. Immun. 2011, 79:688-694.
45. Slansky J.E., Rattis F.M., Boyd L.F., Fahmy T., Jaffee E.M., Schneck J.P., Margulies D.H., Pardoll D.M. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 2000, 13:529-538.
46. Sun L., Wu J., Du F., Chen X., Chen Z.J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 2013, 339:786-791.
47. Wallace A., LaRosa D.F., Kapoor V., Sun J., Cheng G., Jassar A., Blouin A., Ching L.M., Albelda S.M. The vascular disrupting agent, DMXAA, directly activates dendritic cells through a MyD88-independent mechanism and generates antitumor cytotoxic T lymphocytes. Cancer Res. 2007, 67:7011-7019.
48. Wolchok J.D., Kluger H., Callahan M.K., Postow M.A., Rizvi N.A., Lesokhin A.M., Segal N.H., Ariyan C.E., Gordon R.A., Reed K., et al. Nivolumab plus ipilimumab in advanced melanoma. N.Engl. J. Med. 2013, 369:122-133.
49. Woo S.R., Fuertes M.B., Corrales L., Spranger S., Furdyna M.J., Leung M.Y., Duggan R., Wang Y., Barber G.N., Fitzgerald K.A., et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 2014, 41:830-842.
50. Woodward J.J., Iavarone A.T., Portnoy D.A. c-di-AMP secreted by intracellular Listeria monocytogenes activates a host type I interferon response. Science 2010, 328:1703-1705.
51. Yan H., Wang X., KuoLee R., Chen W. Synthesis and immunostimulatory properties of the phosphorothioate analogues of cdiGMP. Bioorg. Med. Chem. Lett. 2008, 18:5631-5634.
52. Yi G., Brendel V.P., Shu C., Li P., Palanathan S., Cheng Kao C. Single nucleotide polymorphisms of human STING can affect innate immune response to cyclic dinucleotides. PLoS ONE 2013, 8:e77846.
53. Zhang X., Shi H., Wu J., Zhang X., Sun L., Chen C., Chen Z.J. Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. Mol. Cell 2013, 51:226-235.
54. Zhao L., Ching L.M., Kestell P., Baguley B.C. The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. Br. J. Cancer 2002, 87:465-470.